A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Martinez, David R, et al. A Broadly Cross-reactive Antibody Neutralizes and Protects Against Sarbecovirus Challenge In Mice. 2021. https://doi.org/10.17615/s4n5-5505APA
Martinez, D., Schäfer, A., Gobeil, S., Li, D., De La Cruz, G., Parks, R., Lu, X., Barr, M., Stalls, V., Janowska, K., Beaudoin, E., Manne, K., Mansouri, K., Edwards, R., Cronin, K., Yount, B., Anasti, K., Montgomery, S., Tang, J., Golding, H., Shen, S., Zhou, T., Kwong, P., Graham, B., Mascola, J., Montefiori, D., Alam, S., Sempowski, G., Khurana, S., Wiehe, K., Saunders, K., Acharya, P., Haynes, B., & Baric, R. (2021). A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. https://doi.org/10.17615/s4n5-5505Chicago
Martinez, David R., Alexandra Schäfer, Sophie Gobeil, Dapeng Li, Gabriela De La Cruz, Robert Parks, Xiaozhi Lu et al. 2021. A Broadly Cross-Reactive Antibody Neutralizes and Protects Against Sarbecovirus Challenge In Mice. https://doi.org/10.17615/s4n5-5505- Creator
-
Martinez, David R.
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
-
Schäfer, Alexandra
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
-
Gobeil, Sophie
- Other Affiliation: Duke University School of Medicine
-
Li, Dapeng
- Other Affiliation: Duke University School of Medicine
-
De la Cruz, Gabriela
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Parks, Robert
- Other Affiliation: Duke University School of Medicine
-
Lu, Xiaozhi
- Other Affiliation: Duke University School of Medicine
-
Barr, Maggie
- Other Affiliation: Duke University School of Medicine
-
Stalls, Victoria
- Other Affiliation: Duke University School of Medicine
-
Janowska, Katarzyna
- Other Affiliation: Duke University School of Medicine
-
Beaudoin, Esther
- Other Affiliation: Duke University School of Medicine
-
Manne, Kartik
- Other Affiliation: Duke University School of Medicine
-
Mansouri, Katayoun
- Other Affiliation: Duke University School of Medicine
-
Edwards, Robert J.
- Other Affiliation: Duke University School of Medicine
-
Cronin, Kenneth
- Other Affiliation: Duke University School of Medicine
-
Yount, Boyd
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
-
Anasti, Kara
- Other Affiliation: Duke University School of Medicine
-
Montgomery, Stephanie A.
- Affiliation: School of Medicine, Department of Pathology and Laboratory Medicine
-
Tang, Juanjie
- Other Affiliation: FDA
-
Golding, Hana
- Other Affiliation: FDA
-
Shen, Shaunna
- Other Affiliation: Duke University School of Medicine
-
Zhou, Tongqing
- Other Affiliation: NIH
-
Kwong, Peter D.
- Other Affiliation: NIH
-
Graham, Barney S.
- Other Affiliation: NIH
-
Mascola, John R.
- Other Affiliation: NIH
-
Montefiori, David. C.
- Other Affiliation: Duke University School of Medicine
-
Alam, S. Munir
- Other Affiliation: Duke University School of Medicine
-
Sempowski, Gregory D.
- Other Affiliation: Duke University School of Medicine
-
Khurana, Surender
- Other Affiliation: FDA
-
Wiehe, Kevin
- Other Affiliation: Duke University School of Medicine
-
Saunders, Kevin O.
- Other Affiliation: Duke University School of Medicine
-
Acharya, Priyamvada
- Other Affiliation: Duke University School of Medicine
-
Haynes, Barton F.
- Other Affiliation: Duke University School of Medicine
-
Baric, Ralph S.
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
- Abstract
- Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2), including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality associated with sarbecovirus infection underscores the importance of developing broadly effective countermeasures against them, which could be key in the prevention and mitigation of current and future zoonotic events. Here, we demonstrate the neutralization of SARS-CoV, bat coronaviruses WIV-1, RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, B.1.617.1, and B.1.617.2 by a receptor-binding domain (RBD)-specific human antibody, DH1047. Prophylactic and therapeutic treatment with DH1047 was protective against SARS-CoV, WIV-1, RsSHC014, and SARS-CoV-2 B.1.351 infection in mice. Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is highly conserved among sarbecoviruses. Thus, DH1047 is a broadly protective antibody that can prevent infection and mitigate outbreaks caused by SARS-related strains and SARS-CoV-2 variants. Our results also suggest that the conserved RBD epitope bound by DH1047 is a rational target for a universal sarbecovirus vaccine
- Date of publication
- 2021
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Science Translational Medicine
- Page start
- eabj7125
- Language
- English
Relations
- Parents:
- In Collection:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
scitranslmed.abj7125.pdf | 2021-12-01 | Public | Download |